SEC Form 4 · accession 0001185185-26-002764
IGC Pharma, Inc. · IGC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Claudia Grimaldi
Officer — PFO · Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 9:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001326205
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2026 | A | 2,048,378 | $0.27 | A | 3,421,092 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $553,062 of outstanding indebtedness owed by the Issuer to the Reporting Person. The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3.